Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

NCT00250874 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab

Sponsor

Zeneus Pharma